Affiliation
Tullamore General Hospital, Ireland.Issue Date
2012-01-31T16:33:38ZMeSH
Anemia/etiologyAntineoplastic Agents/therapeutic use
Boronic Acids/therapeutic use
Humans
Hypercalcemia/etiology
Immunologic Factors/therapeutic use
Infection/etiology
*Multiple Myeloma/complications/diagnosis/epidemiology/therapy
Nurse's Role
Patient Education as Topic
Plasma Cells/physiology
Protease Inhibitors/therapeutic use
Pyrazines/therapeutic use
Renal Insufficiency/etiology
Stem Cell Transplantation
Thalidomide/analogs & derivatives/therapeutic use
Metadata
Show full item recordCitation
Br J Nurs. 2010 Dec 9-2011 Jan 13;19(22):1415-21.Journal
British journal of nursing (Mark Allen Publishing)PubMed ID
21139523Abstract
Myeloma is a challenging blood cancer characterized by bone destruction, hypercalcaemia, renal insufficiency and anaemia. Although myeloma remains incurable, recent advancements in treatments have resulted in significant improvements in morbidity. The use of immunomodulatory drugs-thalidomide, lenalidomide, pomalidomide (in clinical trials)-and the proteasome inhibitor, bortezomib, in conjunction with conventional chemotherapy and supportive therapies, have resulted in a significant shift in approaches to treatment and an improvement in patients' quality of life. Nurses must remain up-to-date with current treatments for myeloma and their related side-effects. In addition, nurses play a key role in the coordination of a multidisciplinary approach to care for myeloma patients.Language
engISSN
0966-0461 (Print)0966-0461 (Linking)